Acetaminophen/hydrocodone
Phase 1Small molecule
Acetaminophen/hydrocodone is one of 12 small molecule programs targeting Ankle Fracture. It is currently in Phase 1.
1
Indications
3
Total Trials
0
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
26 competitors in Ankle Fracture
#DrugCompanyPhaseTrials
1Aleve
Alnylam PharmaceuticalsApproved
Naropin
FFresenius Kabi Oncology Ltd.
Approved
Oxycontin
PProtega
Approved
MS Contin
HHikma Pharmaceuticals LLC
Approved
Adrenaline
SSamson Clinical Operations Pty Ltd
Approved
Tylenol
KKenvue Brands
Approved
Marcaine
IInnocoll
Phase 3
Forsteo
NovartisApproved
Bayer Aspirin
BayerPhase 1
Forteo
AAlmaject
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hand Surgery1 trial
Post-operative Analgesia in Elective, Soft-tissue Hand Surgery
Terminated·—·Phase 4·NCT02029235·72 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Acetaminophen/hydrocodone. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- UUniversity of California, Davis